Johnson & Johnson: raises annual targets
(CercleFinance.com) - Alongside the publication of its quarterly results, Johnson & Johnson has said that it is raising its FY 2018 targets: it is now looking for adjusted EPS of 8.
13 dollars to 8.18 dollars, for revenues that are now expected to reach between 81 billion and 81.4 billion dollars.
The pharmaceutical group reported adjusted Q3 2018 net income that is up 7.3% at 5.6 billion dollars, or 2.05 dollars per share, while the consensus was expecting two cents less.
Its revenues increased by 3.6% to 20.3 billion dollars, including a 5.5% increase in operating terms (i.e. excluding FX factors). Also excluding changes in the group's consolidation scope, revenues rose by 6.1%, driven by international sales (+8.5%).
Copyright (c) 2018 CercleFinance.com. All rights reserved.
13 dollars to 8.18 dollars, for revenues that are now expected to reach between 81 billion and 81.4 billion dollars.
The pharmaceutical group reported adjusted Q3 2018 net income that is up 7.3% at 5.6 billion dollars, or 2.05 dollars per share, while the consensus was expecting two cents less.
Its revenues increased by 3.6% to 20.3 billion dollars, including a 5.5% increase in operating terms (i.e. excluding FX factors). Also excluding changes in the group's consolidation scope, revenues rose by 6.1%, driven by international sales (+8.5%).
Copyright (c) 2018 CercleFinance.com. All rights reserved.